Cargando…

Head and neck (192)Ir HDR-brachytherapy dosimetry using a grid-based Boltzmann solver

PURPOSE: To compare dosimetry for head and neck cancer patients, calculated with TG-43 formalism and a commercially available grid-based Boltzmann solver. MATERIAL AND METHODS: This study included 3D-dosimetry of 49 consecutive brachytherapy head and neck cancer patients, computed by a grid-based Bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebert, Frank-André, Wolf, Sabine, Kóvacs, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899639/
https://www.ncbi.nlm.nih.gov/pubmed/24474973
http://dx.doi.org/10.5114/jcb.2013.39444
Descripción
Sumario:PURPOSE: To compare dosimetry for head and neck cancer patients, calculated with TG-43 formalism and a commercially available grid-based Boltzmann solver. MATERIAL AND METHODS: This study included 3D-dosimetry of 49 consecutive brachytherapy head and neck cancer patients, computed by a grid-based Boltzmann solver that takes into account tissue inhomogeneities as well as TG-43 formalism. 3D-treatment planning was carried out by using computed tomography. RESULTS: Dosimetric indices D(90) and V(100) for target volume were about 3% lower (median value) for the grid-based Boltzmann solver relative to TG-43-based computation (p < 0.01). The V(150) dose parameter showed 1.6% increase from grid-based Boltzmann solver to TG-43 (p < 0.01). CONCLUSIONS: Dose differences between results of a grid-based Boltzmann solver and TG-43 formalism for high-dose-rate head and neck brachytherapy patients to the target volume were found. Distinctions in D(90) of CTV were low (2.63 Gy for grid-based Boltzmann solver vs. 2.71 Gy TG-43 in mean). In our clinical practice, prescription doses remain unchanged for high-dose-rate head and neck brachytherapy for the time being.